Thursday, June 19th, 2025
Stock Profile: ABOS

Acumen Pharmaceuticals, Inc. (ABOS)

Market: NASD | Currency: USD

Address: 427 Park Street

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.




📈 Acumen Pharmaceuticals, Inc. Historical Chart






📊 Statistics





💰 Dividend History


No dividend history available.



📅 Earnings & EPS History for Acumen Pharmaceuticals, Inc.


DateReported EPS
2026-03-25 (estimated upcoming)-
2025-11-10 (estimated upcoming)-
2025-11-09 (estimated upcoming)-
2025-08-11 (estimated upcoming)-
2025-08-10 (estimated upcoming)-
2025-05-12-
2025-05-11-
2025-03-27-0.62
2025-03-23-
2024-11-12-0.5
2024-08-13-0.34
2024-08-12-0.34
2024-05-14-0.25
2024-05-13-0.25
2024-03-26-0.28
2024-03-25-0.28
2023-11-13-0.24
2023-11-12-0.24
2023-08-08-0.28
2023-08-07-0.28
2023-05-09-0.28
2023-05-08-0.28
2023-03-27-0.32
2023-03-26-0.32
2022-11-14-0.26
2022-11-13-0.26
2022-08-15-0.25
2022-08-14-0.25
2022-05-16-0.23
2022-05-15-0.23
2022-03-28-0.42
2022-03-27-0.42
2021-11-15-0.1
2021-11-14-0.1
2021-08-16-7.91
2021-08-15-7.91
2021-07-02-
2021-07-01-




📰 Related News & Research


No related articles found for "acumen pharmaceuticals".